Using illicit drugs alone in Vancouver, Canada: a gender-based analysis.

Kat Gallant, Kanna Hayashi, Eric C Sayre, JinCheol Choi, Manal Mansoor, Thomas Kerr
Author Information
  1. Kat Gallant: British Columbia Centre On Substance Use, Vancouver, BC, Canada.
  2. Kanna Hayashi: British Columbia Centre On Substance Use, Vancouver, BC, Canada.
  3. Eric C Sayre: British Columbia Centre On Substance Use, Vancouver, BC, Canada.
  4. JinCheol Choi: British Columbia Centre On Substance Use, Vancouver, BC, Canada.
  5. Manal Mansoor: British Columbia Centre On Substance Use, Vancouver, BC, Canada.
  6. Thomas Kerr: British Columbia Centre On Substance Use, Vancouver, BC, Canada. bccsu-tk@bccsu.ubc.ca.

Abstract

OBJECTIVES: Canada continues to experience an epidemic of toxic drug-related overdose deaths. Public health messaging emphasizes the dangers of using drugs alone as it restricts timely overdose response or renders it impossible, yet this practice remains prevalent among people who use drugs. While drug use practices and associated harms are known to be highly gendered, little is known about how factors shaping solitary drug use may differ across genders (including cisgender men, cisgender women, transgender women, Two-Spirit people and gender diverse people). Thus, we sought to explore solitary drug use practices according to gender in Vancouver, Canada.
METHODS: Data were collected through Vancouver Injection Drug Users Study, a prospective cohort study between June 2019 and May 2023. We used gender-stratified multivariable generalized estimating equation models to identify factors associated with using drugs alone.
RESULTS: Among the 697 participants, 297 (42.6%) reported using drugs alone in the previous 6 months at baseline. In multivariable analyses, we found that being in a relationship was negatively associated with using alone for both cisgender men and cisgender women (adjusted odds ratio [AOR]���=���0.25 and 0.34, respectively), while homelessness was negatively associated for cisgender men only (AOR���=���0.45). Factors positively associated for cisgender men included daily illicit stimulant use (AOR���=���1.90), and binge drug use (AOR���=���2.18). For cisgender women, only depression was positively associated with using drugs alone (AOR���=���2.16). All p-values���<���0.05. While unable to conduct a multivariable analysis on transgender, Two-Spirit and gender diverse people due to small sample sizes, bivariate analyses showed larger impact of depression on using alone for Two-Spirit (OR���=���8.00) and gender diverse people (OR���=���5.05) compared to others, and only gender diverse people's risk was impacted by experiences of violence (OR���=���9.63). All p-values���<���0.05.
CONCLUSION: The findings of this study suggest significant heterogeneity in gender-specific factors associated with using drugs alone. Factors exclusively impacting cisgender men's risk included homelessness and daily stimulant use, and depression having a significant impact on cisgender women's, but not cisgender men's, risk. Ultimately, gender-specific factors must be recognized in public health messaging, and in developing policies and harm reduction measures to address the risks associated with using alone.

Keywords

References

  1. Harm Reduct J. 2017 Dec 06;14(1):77 [PMID: 29212507]
  2. Subst Use Misuse. 2022;57(12):1864-1872 [PMID: 36096482]
  3. Health Res Policy Syst. 2024 May 23;22(1):60 [PMID: 38783308]
  4. Subst Abuse Treat Prev Policy. 2011 Feb 23;6:4 [PMID: 21345231]
  5. Subst Abus. 2021;42(3):284-293 [PMID: 31657675]
  6. Health Place. 2018 Sep;53:86-93 [PMID: 30059897]
  7. Can J Psychiatry. 2020 Nov;65(11):749-769 [PMID: 32302221]
  8. Subst Abuse Treat Prev Policy. 2021 Oct 18;16(1):79 [PMID: 34663374]
  9. Health Place. 2020 May;63:102327 [PMID: 32224291]
  10. J Urban Health. 2022 Oct;99(5):855-864 [PMID: 36044156]
  11. Harm Reduct J. 2021 Aug 5;18(1):85 [PMID: 34353323]
  12. Soc Sci Med. 2007 Aug;65(3):572-85 [PMID: 17475383]
  13. J Affect Disord. 2019 Mar 1;246:82-88 [PMID: 30578950]
  14. BMC Public Health. 2023 May 30;23(1):1020 [PMID: 37254109]
  15. JAMA Psychiatry. 2022 Jan 1;79(1):81-83 [PMID: 34787646]
  16. Addict Behav. 2021 Apr;115:106793 [PMID: 33421746]
  17. Drug Alcohol Depend. 2013 Oct 1;132(3):603-9 [PMID: 23647731]
  18. Harm Reduct J. 2020 Jan 10;17(1):6 [PMID: 31924209]
  19. J Subst Use Addict Treat. 2024 Feb;157:209190 [PMID: 37866442]
  20. Harm Reduct J. 2020 Nov 23;17(1):90 [PMID: 33228676]
  21. Am J Drug Alcohol Abuse. 1995 Aug;21(3):327-44 [PMID: 7484983]
  22. Drug Alcohol Depend. 2021 Aug 1;225:108797 [PMID: 34102506]
  23. Addiction. 2023 May;118(5):847-854 [PMID: 36468191]
  24. Lancet Public Health. 2020 Jan;5(1):e62-e70 [PMID: 31910981]
  25. Addiction. 2018 Dec;113(12):2261-2270 [PMID: 30211453]
  26. Drug Alcohol Depend Rep. 2024 May 23;12:100240 [PMID: 39035468]
  27. Int J Drug Policy. 2024 Jun;128:104444 [PMID: 38754243]
  28. J Adolesc Health. 2013 Apr;52(4):499-501 [PMID: 23299006]
  29. Harm Reduct J. 2022 Nov 18;19(1):126 [PMID: 36401299]
  30. Front Public Health. 2022 Jul 12;10:900733 [PMID: 35903371]
  31. Harm Reduct J. 2022 Nov 17;19(1):125 [PMID: 36397146]
  32. Drug Alcohol Depend. 2009 Jan 1;99(1-3):176-82 [PMID: 18805655]
  33. Int J Drug Policy. 2020 Jun;80:102769 [PMID: 32446183]
  34. Harm Reduct J. 2021 Mar 7;18(1):29 [PMID: 33678163]
  35. Soc Sci Med. 2018 Jul;208:25-33 [PMID: 29758475]
  36. J Gerontol B Psychol Sci Soc Sci. 2023 Feb 19;78(2):280-290 [PMID: 36315577]
  37. Int J Drug Policy. 2019 Sep;71:169-177 [PMID: 30926217]
  38. BMJ Open. 2019 Jun 27;9(6):e024886 [PMID: 31248914]
  39. AIDS. 2003 Apr 11;17(6):887-93 [PMID: 12660536]
  40. Cochrane Database Syst Rev. 2015 Jan 20;1:CD007505 [PMID: 25601826]
  41. Subst Use Misuse. 2024;59(3):450-458 [PMID: 37964569]
  42. Cochrane Database Syst Rev. 2018 Apr 24;4:CD008581 [PMID: 29688573]
  43. Addiction. 2013 Jul;108(7):1270-6 [PMID: 23551565]
  44. CMAJ. 2023 Oct 16;195(40):E1364-E1379 [PMID: 37844924]
  45. MMWR Morb Mortal Wkly Rep. 2018 Aug 31;67(34):945-951 [PMID: 30161105]
  46. AIDS Behav. 2023 Mar;27(3):957-968 [PMID: 36198856]
  47. Int J Drug Policy. 2020 Apr;78:102733 [PMID: 32247720]
  48. Harm Reduct J. 2022 Mar 21;19(1):29 [PMID: 35313903]
  49. AIDS. 1997 Jul;11(8):F59-65 [PMID: 9223727]
  50. Am J Addict. 2024 May;33(3):283-289 [PMID: 37924248]
  51. Drug Alcohol Rev. 2005 May;24(3):245-51 [PMID: 16096128]
  52. J Urban Health. 2005 Jun;82(2):276-84 [PMID: 15872188]
  53. Drug Alcohol Depend. 2011 Nov 1;118(2-3):500-3 [PMID: 21592681]
  54. Harm Reduct J. 2023 Jun 24;20(1):80 [PMID: 37355610]
  55. Am J Mens Health. 2019 May-Jun;13(3):1557988319859113 [PMID: 31216926]
  56. Int J Drug Policy. 2018 Jun;56:81-91 [PMID: 29614392]
  57. J Clin Psychopharmacol. 1995 Jun;15(3):163-74 [PMID: 7635993]
  58. Int J Drug Policy. 2019 Mar;65:8-23 [PMID: 30580114]
  59. BMJ Evid Based Med. 2020 Aug;25(4):130 [PMID: 31554608]
  60. Harm Reduct J. 2024 Feb 5;21(1):31 [PMID: 38317194]
  61. Addiction. 2019 Mar;114(3):574-575 [PMID: 30461114]
  62. PLoS One. 2020 Sep 11;15(9):e0238618 [PMID: 32915834]
  63. Drug Alcohol Depend. 2001 Aug 1;63(3):207-14 [PMID: 11418225]
  64. Subst Use Misuse. 2022;57(13):1988-1996 [PMID: 36151968]
  65. Soc Sci Med. 2017 May;180:125-134 [PMID: 28343111]
  66. Harm Reduct J. 2023 Oct 27;20(1):158 [PMID: 37891630]
  67. PLoS One. 2019 Nov 14;14(11):e0224993 [PMID: 31725737]
  68. Subst Use Misuse. 2020;55(13):2079-2086 [PMID: 32646279]
  69. Int J Drug Policy. 2020 Feb;76:102641 [PMID: 31887644]
  70. CMAJ. 2018 Mar 5;190(9):E247-E257 [PMID: 29507156]
  71. Am J Respir Crit Care Med. 2020 Jul 15;202(2):e5-e31 [PMID: 32663106]

Grants

  1. U01DA038886/NIH HHS
  2. U01DA038886/NIH HHS

MeSH Term

Humans
Male
Female
Adult
Illicit Drugs
Prospective Studies
Sex Factors
Canada
Middle Aged
British Columbia
Ill-Housed Persons
Transgender Persons
Substance-Related Disorders

Chemicals

Illicit Drugs

Word Cloud

Created with Highcharts 10.0.0aloneusingassociateddrugsusecisgenderpeoplegenderdrugfactorsmendiversewomenTwo-SpiritVancouvermultivariabledepression05riskUseCanadaoverdosehealthmessagingpracticesknownsolitarytransgenderDrugstudyanalysesnegativelyhomelessnessFactorspositivelyincludeddailyillicitstimulantAOR���=���2p-values���<���0analysisimpactsignificantgender-specificcisgender men'sUsingOBJECTIVES:continuesexperienceepidemictoxicdrug-relateddeathsPublicemphasizesdangersrestrictstimelyresponserendersimpossibleyetpracticeremainsprevalentamongharmshighlygenderedlittleshapingmaydifferacrossgendersincludingThussoughtexploreaccordingMETHODS:DatacollectedInjectionUsersStudyprospectivecohortJune2019May2023usedgender-stratifiedgeneralizedestimatingequationmodelsidentifyRESULTS:Among697participants297426%reportedprevious6 monthsbaselinefoundrelationshipadjustedoddsratio[AOR]���=���025034respectivelyAOR���=���045AOR���=���190binge18cisgender women16unableconductduesmallsamplesizesbivariateshowedlargerOR���=���800OR���=���5comparedotherspeople'simpactedexperiencesviolenceOR���=���963CONCLUSION:findingssuggestheterogeneityexclusivelyimpactingcisgender women'sUltimatelymustrecognizedpublicdevelopingpoliciesharmreductionmeasuresaddressrisksCanada:gender-basedGenderPeopleDrugsSolitarySubstanceAlone

Similar Articles

Cited By